Krankenhaus Nordwest GmbH — Clinical Trial Site

133 Registered trials

61 Currently recruiting

Organisation

Krankenhaus Nordwest GmbH

Location

Frankfurt Am Main, Germany

Identifier

ORG-100041682

Address

Steinbacher Hohl 2-26, Praunheim, 60488, Germany

Departments

-
#2602: Institut für Klinisch-Onkologische Forschung (IKF)
Clinic for Pulmonology, Respiratory and Intensive Care Medicine, Gastroenterology, Cardiology
Clinic for thorax oncology
Department of Oncology and Hematology Krankenhaus Nordwest
Forschung der Krankenhaus Nordwest GmbH
II. Medizinische Klinik
IKF
IKF Hospital Northwest
Innere Medizin/Hämatologie/Onkologie
Institut fuer Klinisch- Onkologische Forschung (IKF)
Institut fuer Klinisch-Onkologische Forschung (IKF), DEU01-0
Institut fuer Klinisch-Onkologische Forschung
Institut fuer Klinisch-Onkologische Forschung (IKF)
Institut fuer Klinische Krebsforschung (IKF)
Institut Fuer KlinischOnkologische Forschung (IKF)
Institut für Klinisch Onkologische Forschung
Institut für Klinisch Onkologische Forschung am Krankenhaus Nordwest
Institut für Klinisch-Onkologische Forschung
Institut für Klinisch-Onkologische Forschung (IKF)
Institut für Klinisch-Onkologische Forschung (IKF
Institut für Klinisch-Onkologische Forschung (IKF)
Institut für Klinisch-Onkologische Forschung (IKF),UCT-Frankfurt
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest
Institut für Klinisch-Onkologische Forschung Universitäres Centrum für Tumorerkrankungen
Institut für Klinisch-Onkologische Krebsforschung
Institut für Klinische Krebsforschung IKF
Institute of Clincial Cancer Research
Institute of Clinical Cancer Research
Institute of clinical cancer research (IKF)
Institute of Clinical Cancer Research IKF
Institute of Clinical Cancer Research(IKF)
Klinik f. Onkologie und Hämatologie
Klinik für Hämatologie und Onkologie
Klinik für Onkologie und Hämatologie
Klinik für Onkologie, Sektion Thoraxonkologie
Klinik für Radioonkologie
Klinik für Thoraxonkologie
Klinik für Urologie
Klinisch-Onkologische Forschung
Klink für Onkologie und Hämatologie
n.a.
N/A
NA
Neurologische Klinik
Oncology and Hematology
Onkologie
Onkologie und Haematologie
Onkologie und Hämatologie - Medizinische Klinik II
Thoraxonkologie
UCT - University Cancer Center Frankfurt
Upper-GastroIntestinal-tract
Urology

Clinical trials at this site (133)

Search interface

A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting

2023-504888-16-00 Patients with Human Epidermal Growth Factor Receptor 2 9 2020-10-05
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Untreated Metastatic Pancreatic Ductal Adenocarcinoma 10 2025-12-17
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended

2024-517817-34-00 Gastric Cancer 9 2025-06-18
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended

2024-517818-15-00 Non-Small Cell Lung Cancer 9 2025-06-06
A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors. Ended

2024-516733-12-00 Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung C 1 2025-05-13
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment… Ended

2024-515936-62-00 Patients with advanced or metastatic gastrointestinal ( 9 2024-10-10
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended

2023-508219-21-00 BTC - Biliary Tract Cancer 5 2024-09-12
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended

2023-509633-39-00 Advanced solid tumours 7 2024-08-06
A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended

2023-506054-20-00 Adenocarcinoma of the biliary tract (intrahepatic or ex 5 2024-06-05
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended

2023-507516-12-00 Solid Tumors 4 2024-05-08
TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended

2023-505722-33-00 cholangiocarcinoma or gallbladder carcinoma 4 2024-04-15
Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended

2023-503265-27-00 Participants with Untreated T4N0 or Stage III dMMR/MSI- 5 2023-11-23
SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended

2022-502012-37-00 Advanced Hepatocellular Carcinoma 5 2023-10-06
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f… Ended

2024-515224-37-00 Patients with MSI-high or MMR-deficient stage III color 4 2023-08-29
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 4 2023-08-28
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended

2022-502634-52-00 prostate cancer 5 2023-05-16